Format

Send to

Choose Destination
J Infect Dis. 2015 Nov 15;212(10):1677-82. doi: 10.1093/infdis/jiv262. Epub 2015 May 5.

Macrophage Migration Inhibitory Factor Is Detrimental in Pneumococcal Pneumonia and a Target for Therapeutic Immunomodulation.

Author information

1
Department of Microbiology.
2
Department of Microbiology Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
3
Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
4
Department of Medicine, Yale School of Medicine.
5
Department of Chemistry, Yale University, New Haven, Connecticut.

Abstract

Mortality from pneumococcal pneumonia remains high despite antibiotic therapy, highlighting the pathogenic potential for host inflammation. We demonstrate that macrophage migration inhibitory factor (MIF), an innate immune mediator, is detrimental for survival and associated with lung pathology, inflammatory cellular infiltration, and bacterial replication in a mouse model of pneumococcal pneumonia, despite being necessary for clearance from the nasopharynx. Treatment of animals with a small-molecule inhibitor of MIF improves survival by reducing inflammation and improving bacterial control. Our work demonstrates that MIF modulates beneficial versus detrimental inflammatory responses in the host-pneumococcal interaction and is a potential target for therapeutic modulation.

KEYWORDS:

macrophage migration inhibitory factor; pneumococcus; pneumonia

PMID:
25943202
PMCID:
PMC4621247
DOI:
10.1093/infdis/jiv262
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center